Ligand Partner Spectrum Pharmaceuticals Receives FDA Approval of EVOMELA™ (melphalan) for Injection
Ligand Reports Fourth Quarter and Full Year 2015 Financial Results
Ligand Enters Into OmniAb® Platform License Agreement with Tizona Therapeutics
Ligand to Report Fourth Quarter and Full Year 2015 Results on February 10th
Ligand Enters Into OmniAb® Platform License Agreement with Emergent BioSolutions
Ligand to Acquire OMT, Inc., a Leader in Human Antibody Generation, for $178 Million in Cash and Stock
RODES Signs Exclusive Captisol® Licensing Agreement with Ligand Pharmaceuticals for Three Programs
Ligand Provides Highlights from Today’s Analyst Day Event
Ligand Reports Third Quarter 2015 Financial Results
